


PHARMACEUTICAL 2022

Oncorus Inc. Rank 231 of 475







PHARMACEUTICAL 2022

Oncorus Inc. Rank 231 of 475

The relative strengths and weaknesses of Oncorus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncorus Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Oncorus Inc. is the variable Revenues, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 189% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	129,110
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,974
Liabilities, Non-Current	50,591
Other Assets	49,244
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	56
Property and Equipment	23,233
Research and Development	44,682
Revenues	0
Selling, General and Administrative Expense	20,136

Output Variable	Value in 1000 USD
Assets	201,587
Liabilities	71,565
Expenses	64,818
Stockholders Equity	130,022
Net Income	-64,762
Comprehensive Net Income	-64,762
Economic Capital Ratio	-88%

